PLG — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Hydrochloric Acid (SCHEMBL250043)	0.51	17/20
Nafamostat (SCHEMBL135503)	0.64	9/20
SCHEMBL111906	0.53	8/20
SCHEMBL327252	0.51	5/20
SCHEMBL326662	0.77	4/20
SCHEMBL373315	0.52	4/20
SCHEMBL373982	0.51	4/20
SCHEMBL49084	0.73	3/20
SCHEMBL57970	0.70	3/20
SCHEMBL330715	0.59	3/20
SCHEMBL124239	0.52	3/20
SCHEMBL202931	0.46	3/20
Nafamostat (SCHEMBL135504)	1.00	2/20
SCHEMBL231914	0.95	2/20
SCHEMBL130730	0.61	2/20
SCHEMBL221369	0.60	2/20
SCHEMBL330274	0.57	2/20
SCHEMBL219871	0.56	2/20
SCHEMBL331211	0.54	2/20
SCHEMBL49594	0.53	2/20

Clinical trials — most relevant to PLG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The OPTIMA-5 Trail	PHASE4	COMPLETED
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction	PHASE4	RECRUITING
Role Of Different Prophylactic Doses Of Intravenous Tranexamic Acid In Reducing Blood Loss At Caesarean Section	PHASE4	COMPLETED
Study the Anti-inflammatory Effect of Tranexamic Acid When Used in Anterior Cruciate Ligament Reconstruction.	PHASE4	NOT_YET_RECRUITING
Study of Alfimeprase to Rapidly Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery on Leg Arteries	PHASE3	COMPLETED
Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial	PHASE3	RECRUITING
Fibrinogen Replacement to Prevent Intracranial Haemorrhage in Ischemic Stroke Patients After Thrombolysis (FibER)	PHASE3	COMPLETED
Topical Tranexamic Acid in Caesarean Section	PHASE3	UNKNOWN
The Effects of DLBS1033 on Haemostasis Parameters in Healthy Volunteers	PHASE2	COMPLETED
A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion	PHASE2	COMPLETED
Injection of Recombinant Human Tissue-type Plasminogen Activator Derivative for Acute Pulmonary Embolism(rPA)	PHASE2	UNKNOWN
A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients	PHASE1/PHASE2	COMPLETED
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection	PHASE2	COMPLETED
A Dose Escalation and Safety Study of Plasmin (Human) In Acute Lower Extremity Native Artery or Bypass Graft Occlusion	PHASE1	COMPLETED
Intra-arterial Thrombolysis for Severe Recent Central Retinal Vein Occlusion	PHASE1	COMPLETED
A Lifestyle Intervention to Improve in Vitro Fertilization Results	nan	UNKNOWN
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery	nan	ENROLLING_BY_INVITATION
The Immunomodulatory Effect of Antrifibrinolytic (Tranexamic Acid) in Total Knee Arthroplasty	nan	UNKNOWN
Prevalence of Clinical and Laboratory Markers of Hypofibrinolysis in Psychotic Patients	nan	COMPLETED
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease	nan	RECRUITING
Surgical Revascularisation and Nerve Stimulation Trial	nan	WITHDRAWN
Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia	nan	UNKNOWN
Heparin Responses in Pediatric Patients Undergoing Cardiopulmonary Bypass.	nan	COMPLETED
Defining the Temporal Changes in the Acute Phase Response During Graded Exercise: A Prospective Study	nan	ENROLLING_BY_INVITATION
A Treatment Protocol for Expanded Access Administration of Prometic Plasminogen Due to Closure of Clinical Trial	nan	NO_LONGER_AVAILABLE
Study of Individuals Affected With Hypoplasminogenemia	nan	RECRUITING
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE)	nan	COMPLETED
SuPAR in Adult Patients With Covid-19	nan	COMPLETED
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence	nan	WITHDRAWN
Fibrinolysis Resistance in Infection and Trauma	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PLG binder may also engage these)

Protein	Name	Similarity
Q5R8X6	—	1.000	Q5R8X6 →
P06868	—	1.000	P06868 →
P20918	—	1.000	P20918 →
P12545	—	1.000	P12545 →
O18783	—	1.000	O18783 →
Q29485	—	1.000	Q29485 →
Q01177	—	1.000	Q01177 →
P06867	—	0.998	P06867 →
Q08048	—	0.996	Q08048 →
HGF	Hepatocyte growth factor	0.996	landscape →
P17945	—	0.995	P17945 →
P19637	—	0.994	P19637 →
P11214	—	0.993	P11214 →
P49150	—	0.992	P49150 →
P29598	—	0.992	P29598 →
Q5R8J0	—	0.991	Q5R8J0 →
Q9BH09	—	0.991	Q9BH09 →
Q8SQ23	—	0.990	Q8SQ23 →
P26928	—	0.989	P26928 →
Q867B7	—	0.989	Q867B7 →
Q76BS1	—	0.989	Q76BS1 →
Q5E9Z2	—	0.989	Q5E9Z2 →
Q8MHY7	—	0.988	Q8MHY7 →
P04185	—	0.988	P04185 →
Q28198	—	0.987	Q28198 →
P98121	—	0.987	P98121 →
Q5G265	—	0.987	Q5G265 →
MST1	Hepatocyte growth factor-like protein	0.986	landscape →
Q62381	—	0.986	Q62381 →
O57460	—	0.986	O57460 →